MetaCap

Corbus Pharmaceuticals (CRBP) vs Elicio Therapeutics (ELTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elicio Therapeutics (ELTX) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 82.8% versus a loss of 82.8%. Over five years, CRBP leads with a -92.2% price change compared with -96.1% for ELTX. Corbus Pharmaceuticals is the larger company by market cap ($42.4 million vs $41.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRBP-82.85%ELTX-82.84%
+84%-4%-91%
Nov 21, 20251 yearNov 20, 2026
CRBP-92.63%ELTX-96.46%
+130%+11%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRBP versus ELTX key metrics
MetricCRBPELTX
Share price$2.06$1.45
Market cap$42.45M$41.05M
1-day change-15.40%-3.33%
YTD return-74.69%-81.78%
1-year return-82.85%-82.84%
5-year return-92.23%-96.13%
EPS (TTM)$-6.04$-1.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-78.54M$-39.57M
52-week high$12.88$16.00
52-week low$2.01$1.25
Distance from 52-week high-84.01%-90.94%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1551.94%+842.76%
Average volume1.11M324.71K
Shares outstanding20.61M28.31M
Employees3633
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Corbus Pharmaceuticals

CRBP stock →

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

CRBP vs ELTX FAQ

Which is bigger, Corbus Pharmaceuticals or Elicio Therapeutics?

Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $42.45M compared with $41.05M for Elicio Therapeutics (ELTX).

Which stock has performed better over the past year, CRBP or ELTX?

ELTX returned -82.84% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.

Are Corbus Pharmaceuticals and Elicio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons